WuXi Biologics NDR takeaways: manufacturing ramp-up and IP revenue support growth, while geopolitics remains the key uncertainty

Overview

This report is Morgan Stanley's Asia Pacific NDR takeaways on WuXi Biologics Cayman Inc (2269.HK). The report argues that onshore and offshore capital continue to pay close attention to WuXi Biologics; the company has made progress in the manufacturing phase and benefited from rising IP revenue. Although the market is concerned about geopolitical factors, the United States remains the company's largest revenue driver and market, and active out-licensing among innovative Chinese biopharma companies is also supporting related contract growth.

Core views

The core views are: first, 2026 revenue growth guidance is 13%-17%, with phase III and commercial manufacturing revenue expected to grow by about 30%, although management is also factoring in U.S. dollar depreciation and macro uncertainty. Second, 2025 gross margin rose from 41% to 46%, driven by a higher-priced project mix, research services or IP revenue, improved development-stage efficiency, and better capacity utilization; management expects gross margin to remain stable in 2026. Third, IP revenue has become an important profit contributor, reaching US$150mn in 2025, up 50% year over year, including prepayments from Vertex and Zai Lab, and contributing about 14% of pre-tax profit. Fourth, bispecific/multispecific antibodies and ADCs (through WuXi XDC) are the biggest drivers of growth and backlog, and biosimilars may become more important in the future.

Analysis framework

The report mainly draws on the NDR meeting notes and the Morgan Stanley ModelWare framework, and organizes WuXi Biologics' growth drivers and valuation assumptions based on the company's revenue guidance, gross margin changes, IP revenue, capital expenditure, capacity planning, project pipeline, and risk factors.

Methodology notes

• Valuation methodDiscounted cash flow

  DCF

  The report discloses that the base-case valuation uses the discounted cash flow method, assuming an 8.4% WACC, a 4% terminal growth rate, and an HKD:RMB exchange rate of 0.9.

• Research frameworkMorgan Stanley ModelWare

  Internal model framework

  Unless otherwise stated, the metrics in the report are based on the Morgan Stanley ModelWare framework.

• Rating systemMorgan Stanley relative rating system

  Overweight, Equal-weight, Underweight

  Morgan Stanley does not use Buy, Hold, or Sell as formal stock ratings; instead, it uses Overweight, Equal-weight, Not-Rated, and Underweight relative to the covered universe, typically assessing 12-18 month risk-adjusted total return.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• WuXi Biologics Cayman Inc (2269.HK)

  Subject company

  Strengths

  Progress in the manufacturing phase, higher IP revenue, ADC and bispecific/multispecific antibody projects driving backlog, and the U.S. market remaining the largest revenue source.

  Weaknesses

  Revenue guidance remains affected by U.S. dollar depreciation, macro uncertainty, and geopolitical concerns.

  Comparison

  Compared with general early-stage research services, the report places greater emphasis on late-stage and commercial manufacturing, as well as the contribution of high-value project mix to growth and gross margin.

  Risks

  Slower biopharma projects, weaker R&D outsourcing intensity, IP protection or reputational risks, and geopolitical risk.

• WuXi XDC Cayman Inc

  WuXi Biologics-related ADC business platform

  Strengths

  ADC is identified in the report as one of the biggest drivers of growth and backlog.

  Weaknesses

  Dependent on ADC demand and the pace of client project progression.

  Comparison

  Compared with traditional biologics manufacturing, ADC and bispecific/multispecific antibody projects have higher growth contribution and higher contract value characteristics.

  Risks

  Clinical progress, regulation, outsourcing demand, and changes in the competitive landscape.

Key data

• 2026 Revenue Growth Guidance13%-17%Includes an expected approximately 30% growth in phase III and commercial manufacturing revenue, while also factoring in U.S. dollar depreciation and macro uncertainty.
• 2025 Gross Margin41% to 46%Margin expansion was driven by improved project mix, IP revenue, efficiency gains, and higher utilization across China and overseas facilities.
• 2025 IP RevenueUS$150mnUp 50% year over year, including prepayments from Vertex and Zai Lab, and contributed about 14% of pre-tax profit.
• 2026 Capital ExpenditureRmb7.1bnChina accounts for 30% and overseas for 70%, mainly allocated to Singapore and the United States.
• Drug Substance Capacityabout 300,000L; expected to reach about 370,000L in 2029Year-end capacity has reached about 300,000L and is expected to continue increasing to 2029 as utilization improves.
• Valuation AssumptionsWACC 8.4%; terminal growth rate 4%; HKD:RMB 0.9The base case uses the DCF valuation method.

Impact & implications

The report is positive for WuXi Biologics: ramp-up in late-stage and commercial manufacturing, demand for ADCs and bispecific/multispecific antibodies, IP revenue growth, and overseas capacity investment together support mid-term growth visibility. If outsourcing demand from global pharmaceutical and biotech companies recovers and drug development market growth accelerates, order intake and earnings leverage may improve further; however, if biopharma projects slow, outsourcing intensity declines, or geopolitical risks rise, revenue, valuation, and sentiment could come under pressure.

Risks

• Further slowdown in biopharma projects from pharmaceutical and biotech companies.
• A decline in R&D outsourcing intensity.
• IP protection or company reputation risks.
• Geopolitical risk.
• U.S. dollar depreciation and macro uncertainty affecting the delivery of revenue guidance.
• Overseas capital expenditure and new capacity utilization falling short of expectations.

What to watch

• Whether the 2026 revenue growth guidance of 13%-17% is delivered.
• Whether phase III and commercial manufacturing revenue grows by about 30%.
• Whether gross margin in 2026 can remain stable near the 46% level achieved in 2025.
• Progress on IP revenue and milestone/royalty income from equity-linked projects.
• Changes in backlog for ADC, bispecific/multispecific antibodies, and biosimilars.
• Progress and utilization of overseas capacity in Singapore and the United States.
• The resilience of U.S. market revenue and changes in geopolitical policy.